Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

Project description

Generalising targeted protein degradation using monovalent degraders

Unlike traditional drugs that block activity of disease-causing proteins, bivalent degraders link target proteins to E3 ubiquitin ligases, tagging them for proteasomal destruction. Though effective, this approach is limited to specific targets. Monovalent degraders are also known to induce degradation of otherwise ‘undruggable’ proteins through molecular gluing, but they lack rational design. The ERC-funded TrickE3 project will design versatile strategies for the development of monovalent degraders, aiming to extend the range of druggable protein targets. To achieve this, it will develop novel methodologies to identify and predict drug-induced changes in the activity of E3 ligases at scale. Results will be demonstrated on the chemical rewiring of E3s expressed in pancreatic cancer.

Objective

Classical drug design relies mostly on the availability of accessible pockets to block specific protein activities. Despite tremendous progress, more than 80% of all human proteins remain beyond the reach of traditional inhibitor-centric approaches. Chemical ablation of protein abundance using bivalent degraders (PROTACs) moves away from an occupancy-driven (inhibition) to an event-driven (binding) pharmacology. However, their design is intrinsically limited to targets that are ligandable via chemical probes. To tackle current unmet clinical problems, we need transformative paradigms.
Fortuitous discoveries have illustrated the immense potential of monovalent degraders. These molecules induce the degradation of target proteins by molecular gluing to E3 ubiquitin ligases or by prompting their destabilization. They have desirable drug-like properties, proven capacity to induce the degradation of proteins otherwise deemed undruggable, and they are already a clinical reality. However, their discovery has been driven by serendipity, thereby hampering their realization as a generalizable drug solution.
TrickE3 seeks to establish the foundations for the systematic development of monovalent degraders. To this end, we will develop innovative methodologies to detect and predict drug-induced changes in the interactome/activity of E3s at scale. As proof of principle, we will focus on the chemical rewiring of E3s expressed in pancreatic ductal adenocarcinoma (PDAC) due to the imperative need for treatments. We intend to prospectively identify monovalent degraders (i) of specific vulnerabilities, and (ii) to unlock new PDAC targets.
At the interface of chemical biology and cancer research, TrickE3 will be an instrumental resource to broaden drug discovery efforts, probe disease-relevant vulnerabilities and, overall, widen the targetable space of the human proteome. We hope to empower other disciplines to chemically explore, without limits, the degradation of relevant targets.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2021-STG

See all projects funded under this call

Host institution

FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Net EU contribution
€ 1 499 625,00
Address
CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA
08028 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 1 499 625,00

Beneficiaries (1)